Age and Menopausal Status Affect Osteoprotegerin and Osteocalcin Levels in Women Differently, Irrespective of Thyroid Function
暂无分享,去创建一个
[1] C. Hsieh,et al. The relationship between regional abdominal fat distribution and both insulin resistance and subclinical chronic inflammation in non-diabetic adults , 2014, Diabetology & Metabolic Syndrome.
[2] Merlin C. Thomas,et al. Osteoprotegerin Is an Independent Predictor of Vascular Events in Finnish Adults With Type 1 Diabetes , 2013, Diabetes Care.
[3] S. Cummings,et al. Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON‐PFT, and FREEDOM trials , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] C. Pepene. Serum under-carboxylated osteocalcin levels in women with polycystic ovary syndrome: weight-dependent relationships with endocrine and metabolic traits , 2013, Journal of Ovarian Research.
[5] M. Emoto,et al. Undercarboxylated osteocalcin does not correlate with insulin resistance as assessed by euglycemic hyperinsulinemic clamp technique in patients with type 2 diabetes mellitus , 2012, Diabetology & Metabolic Syndrome.
[6] L. Rasmussen,et al. No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells , 2012, Molecular and Cellular Endocrinology.
[7] M. Muñoz-Torres,et al. Role of serum FSH measurement on bone resorption in postmenopausal women , 2012, Endocrine.
[8] M. Zaidi,et al. Thyroid-stimulating hormone induces a Wnt-dependent, feed-forward loop for osteoblastogenesis in embryonic stem cell cultures , 2011, Proceedings of the National Academy of Sciences.
[9] Soma Sh Abd El Gawad,et al. Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men , 2011, BMC endocrine disorders.
[10] S. Yano,et al. Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. , 2011, Bone.
[11] E. Mathiesen,et al. Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population – the Tromsø study , 2010, Journal of thrombosis and haemostasis : JTH.
[12] S. Yano,et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. , 2009, The Journal of clinical endocrinology and metabolism.
[13] D. Mellström,et al. Plasma Osteocalcin Is Inversely Related to Fat Mass and Plasma Glucose in Elderly Swedish Men , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[14] U. Gaspard. Hyperinsulinaemia, a key factor of the metabolic syndrome in postmenopausal women. , 2009, Maturitas.
[15] B. Dawson-Hughes,et al. Association between serum osteocalcin and markers of metabolic phenotype. , 2009, The Journal of clinical endocrinology and metabolism.
[16] A. Papavassiliou,et al. A possible role of osteocalcin in the regulation of insulin secretion: human in vivo evidence? , 2008, The Journal of endocrinology.
[17] S. Khosla,et al. Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. , 2008, Journal of the American College of Cardiology.
[18] J. Jeon,et al. Relationship between osteocalcin and glucose metabolism in postmenopausal women. , 2008, Clinica chimica acta; international journal of clinical chemistry.
[19] T. Pilli,et al. The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels. , 2008, Thyroid : official journal of the American Thyroid Association.
[20] G. Karsenty,et al. Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice , 2008, Proceedings of the National Academy of Sciences.
[21] P. Kostenuik,et al. Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr(−/−) Mice , 2008, Circulation.
[22] Lin-shuang Zhao,et al. [Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients]. , 2007, Zhonghua yi xue za zhi.
[23] M. McKee,et al. Endocrine Regulation of Energy Metabolism by the Skeleton , 2007, Cell.
[24] J. L. San Millán,et al. Thyroid hormone deficiency and postmenopausal status independently increase serum osteoprotegerin concentrations in women. , 2007, European journal of endocrinology.
[25] M. Inaba,et al. Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. , 2005, European journal of endocrinology.
[26] B. Obermayer-Pietsch,et al. Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment. , 2003, Thyroid : official journal of the American Thyroid Association.
[27] S. Erkaya,et al. Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements , 2003, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[28] L. Hofbauer,et al. The Role of Receptor Activator of Nuclear Factor-κB Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases1 , 2000 .
[29] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[30] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.
[31] A. Kung,et al. Thyroxine suppressive therapy decreases bone mineral density in post‐menopausal women , 1993, Clinical endocrinology.
[32] J B Lian,et al. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. , 1989, Physiological reviews.
[33] M. Górska,et al. Interleukin-6 and its considerable role in the pathogenesis of thyrotoxicosis-related disturbances of bone turnover in postmenopausal women. , 2011, Endokrynologia Polska.
[34] I. Holen,et al. Pathophysiological roles of osteoprotegerin (OPG). , 2009, European journal of cell biology.
[35] X. Qiao,et al. Sex steroids and vascular responses in hypertension and aging. , 2008, Gender medicine.
[36] Z. Belaya,et al. Subclinical hyperthyroidism of variable etiology and its influence on bone in postmenopausal women. , 2007, Hormones.